Phaseline

Targets › VSIR

VSIR (V-type immunoglobulin domain-containing suppressor of T-cell activation): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Oct 2029.

Immunoregulatory receptor which inhibits the T-cell response. May promote differentiation of embryonic stem cells, by inhibiting BMP4 signaling (By similarity). (UniProt, Q9H7M9)

Open in Phaseline: the race on VSIR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
PharmAbcinePMC-309
monoclonal antibody against VISTA ligand
VSIRPhase 1Advanced or Metastatic Solid TumorsOct 2029

Conditions

Advanced or Metastatic Solid Tumors (1)

Modalities

mixed (1)

Companies

PharmAbcine (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.